文献速递术前评估与围术期医学心胸血管麻醉气道管理

遗传性血管性水肿患者的围术期管理:体外循环的特殊考量

Perioperative Management of Patients With Hereditary Angioedema With Special Considerations for Cardiopulmonary Bypass.
PubMed 文献 · Anesth Analg · 2020-01-01

本文综述遗传性血管性水肿(HAE)的病理生理与实验室检测,总结预防性和按需治疗的药理学数据,并讨论心血管手术围术期管理的现有临床资料。HAE 因 C1 酯酶抑制剂(C1-INH)缺乏导致缓激肽生成失调,可致面、肢体、生殖器、肠道、口咽和喉部反复水肿。体外循环期间肝素化血液接触人工表面且肺循环被排除,可致全身激肽释放酶激活和缓激肽生成。

要点

  • HAE 患者围术期需熟悉症状、诊断及按需和预防性治疗药物。
  • 体外循环可致全身激肽释放酶激活和缓激肽生成,即使非 HAE 患者。
  • C1-INH 活性降至约 38% 以下可破坏缓激肽稳态并诱发水肿发作。

核心结论

  • 围术期临床医生应熟悉 HAE 症状、诊断及可用治疗,因患者可能需要气道管理、镇静或麻醉。
  • 体外循环因血液接触人工表面和肺循环排除可致全身激肽释放酶激活和缓激肽生成。

研究设计与样本

  • 综述,总结 HAE 病理生理、实验室检测、预防和按需治疗药理学数据及心血管手术围术期临床资料。

主要发现

  • HAE 多为常染色体显性遗传,主要由 C1 酯酶抑制剂(C1-INH)缺乏所致。
  • C1-INH 活性降至约 38% 以下通过增加激肽释放酶激活破坏缓激肽生成稳态,引起反复血管性水肿。
  • HAE 症状可致衰弱并可能危及生命,累及面部、肢体、生殖器、肠道、口咽和喉部。
  • 生物和药理制剂进展显著改善中重度 HAE 的急性和长期照护,治疗包括按需和/或预防性给药。
  • 推荐自我给药,部分药物可经静脉或皮下途径实施。

临床怎么用

  • 围术期应识别 HAE 症状和诊断,并了解按需及预防性治疗策略。
  • 对需气道管理、镇静或麻醉的 HAE 患者,应熟悉可用治疗并考虑自我给药推荐。
  • 心血管手术使用体外循环时需注意全身激肽释放酶激活和缓激肽生成风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hereditary angioedema (HAE) is a rare autosomal dominant disorder mostly due to the deficiency of C1-esterase inhibitor (C1-INH). Reduced C1-INH activity below ~38% disrupts homeostasis of bradykinin (BK) formation by increasing kallikrein activation and causes recurrent angioedema attacks affecting the face, extremities, genitals, bowels, oropharynx, and larynx. HAE symptoms can be debilitating and potentially life-threatening. The recent clinical developments of biological and pharmacological agents have immensely improved acute and long-term care of patients with moderate-to-severe HAE. The therapies are given as on-demand and/or prophylaxis, and self-administration is highly recommended and performed with some agents via intravenous or subcutaneous route. Perioperative clinicians need to be familiar with the symptoms and diagnosis of HAE as well as available therapies because of the potential need for airway management, sedation, or anesthesia for various medical and surgical procedures and postoperative care. Cardiovascular surgery using cardiopulmonary bypass is a unique condition in which heparinized blood comes into direct contact with an artificial surface while pulmonary circulation, a major reserve of angiotensin-converting enzyme (ACE), becomes excluded. These changes result in systemic kallikrein activation and BK formation even in non-HAE patients. The objectives of this review are (1) to review pathophysiology of HAE and laboratory testing, (2) to summarize pertinent pharmacological data on the prophylactic and on-demand treatment strategies, and (3) to discuss available clinical data for perioperative management in cardiovascular surgery.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Tanaka KA, Mondal S, Morita Y, et al. Perioperative Management of Patients With Hereditary Angioedema With Special Considerations for Cardiopulmonary Bypass. Anesth Analg. 2020. PMID: 32102012. doi:10.1213/ANE.0000000000004710

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。